<span item_type="fundamental" item_id="798727996d7ca546fabe3cee14c6a71d" counter_id="ST/US/XOMAO" env="prod"></span><span item_type="announcement" item_id="548953698119584385" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 13.13 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD 0.44.</p><p></p><h3>Segment Revenue</h3><ul><li>XOMA Royalty received $29.6 million in royalties and milestones from its partners in the first half of 2025, including $11.7 million during the second quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net income for the three and six months ended June 30, 2025, was $9.2 million and $11.6 million, respectively, compared to $16.0 million and $7.4 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>General and Administrative (G&amp;A) expenses for the three and six months ended June 30, 2025, were $7.8 million and $15.9 million, respectively, compared to $11.0 million and $19.5 million for the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>Research and Development (R&amp;D) expenses for the three and six months ended June 30, 2025, were $0.1 million and $1.4 million, respectively, compared to $1.2 million for each of the corresponding periods of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash provided by operating activities was $8.7 million for the six months ended June 30, 2025, compared to - $2.2 million for the corresponding period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>Net cash used in investing activities was - $26.7 million for the six months ended June 30, 2025, compared to - $1.4 million for the corresponding period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>Net cash used in financing activities was - $9.9 million for the six months ended June 30, 2025, compared to - $6.1 million for the corresponding period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>XOMA Royalty deployed $20 million to purchase future mezagitamab royalty and milestone interests held by BioInvent, with additional payments contingent on regulatory milestones.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>XOMA Royalty anticipates becoming cash flow positive on a consistent basis exclusively from cash payments received from royalties as new commercial opportunities emerge.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>The company expects to complete the acquisition of HilleVax in September and LAVA Therapeutics in the fourth quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li><li>Topline data from several key Phase 3 assets are anticipated over the coming quarters, which may drive increased royalty receipts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650dex991.htm"></span></li></ul>

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 8-K: FY2025 Q2 Revenue: USD 13.13 M